Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: The STREAM randomized trial
van Eijk IC et al. – In patients with early arthritis of two to five joints, both aggressive tight-control therapy including adalimumab and conventional therapy resulted in remission rates around 50%, low radiographic damage and excellent functional status after 2 years. Full disease control including radiographic arrest in all patients remains an elusive target even in moderately active early arthritis.
Patients with 2 to 5 swollen joints, Sharp–van der Heijde radiographic score (SHS) <5 and symptom duration ≤2 years were randomized between 2 strategies
Patients with a definite non-RA diagnosis excluded
Protocol of aggressive group aimed for remission (DAS<1.6), with consecutive treatment steps: MTX, addition of adalimumab and combination therapy
Conventional care group followed a strategy with traditional DMARDs (no prednisone or biologics) without DAS-based guideline
Outcome measures after 2 years were SHS (primary), remission rate and HAQ score (secondary)
82 patients participated (60% ACPA positive)
In aggressive group (n equals 42), 19 patients were treated with adalimumab
In conventional care group (n equals 40), 24 patients started with hydroxychloroquin (HCQ), 2 with sulfasalazine (SSZ) and 14 with MTX
After 2 years, median SHS increase was 0 [interquartile range (IQR) 0–1.1] and 0.5 (IQR 0–2.5), remission rates were 66 and 49% and HAQ decreased with a mean of −0.09 (0.50) and −0.25 (0.59) in aggressive and conventional care group
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.